Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00702-4
Abstract: Background Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood–brain barrier. Objective We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients… read more here.
Keywords: progression; cns progression; cns non; non cns ... See more keywords